372 related articles for article (PubMed ID: 23576556)
21. Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Mertz JA; Conery AR; Bryant BM; Sandy P; Balasubramanian S; Mele DA; Bergeron L; Sims RJ
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16669-74. PubMed ID: 21949397
[TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of BET bromodomains.
Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE
Nature; 2010 Dec; 468(7327):1067-73. PubMed ID: 20871596
[TBL] [Abstract][Full Text] [Related]
23. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
24. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
[TBL] [Abstract][Full Text] [Related]
25. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
26. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
Fish PV; Filippakopoulos P; Bish G; Brennan PE; Bunnage ME; Cook AS; Federov O; Gerstenberger BS; Jones H; Knapp S; Marsden B; Nocka K; Owen DR; Philpott M; Picaud S; Primiano MJ; Ralph MJ; Sciammetta N; Trzupek JD
J Med Chem; 2012 Nov; 55(22):9831-7. PubMed ID: 23095041
[TBL] [Abstract][Full Text] [Related]
27. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia.
Ali I; Cha HJ; Lim B; Chae CH; Youm J; Park WJ; Lee SH; Kim JH; Jeong D; Lim JK; Hwang YH; Roe JS; Woo JS; Lee K; Choi G
Eur J Med Chem; 2024 Feb; 265():116052. PubMed ID: 38134745
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
30. Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice.
Lee DU; Katavolos P; Palanisamy G; Katewa A; Sioson C; Corpuz J; Pang J; DeMent K; Choo E; Ghilardi N; Diaz D; Danilenko DM
Toxicol Appl Pharmacol; 2016 Jun; 300():47-54. PubMed ID: 27078884
[TBL] [Abstract][Full Text] [Related]
31. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.
Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y
Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820
[TBL] [Abstract][Full Text] [Related]
32. Naphthyridines as novel BET family bromodomain inhibitors.
Mirguet O; Lamotte Y; Chung CW; Bamborough P; Delannée D; Bouillot A; Gellibert F; Krysa G; Lewis A; Witherington J; Huet P; Dudit Y; Trottet L; Nicodeme E
ChemMedChem; 2014 Mar; 9(3):580-9. PubMed ID: 24000170
[TBL] [Abstract][Full Text] [Related]
33. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
34. Bromodomains as therapeutic targets in cancer.
Barbieri I; Cannizzaro E; Dawson MA
Brief Funct Genomics; 2013 May; 12(3):219-30. PubMed ID: 23543289
[TBL] [Abstract][Full Text] [Related]
35. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
37. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
38. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.
Picaud S; Leonards K; Lambert JP; Dovey O; Wells C; Fedorov O; Monteiro O; Fujisawa T; Wang CY; Lingard H; Tallant C; Nikbin N; Guetzoyan L; Ingham R; Ley SV; Brennan P; Muller S; Samsonova A; Gingras AC; Schwaller J; Vassiliou G; Knapp S; Filippakopoulos P
Sci Adv; 2016 Oct; 2(10):e1600760. PubMed ID: 27757418
[TBL] [Abstract][Full Text] [Related]
39. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest.
Ottinger M; Christalla T; Nathan K; Brinkmann MM; Viejo-Borbolla A; Schulz TF
J Virol; 2006 Nov; 80(21):10772-86. PubMed ID: 16928766
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.
Vidler LR; Filippakopoulos P; Fedorov O; Picaud S; Martin S; Tomsett M; Woodward H; Brown N; Knapp S; Hoelder S
J Med Chem; 2013 Oct; 56(20):8073-88. PubMed ID: 24090311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
